Danenberg, Esther http://orcid.org/0000-0002-1799-4457
Bardwell, Helen
Zanotelli, Vito R. T.
Provenzano, Elena http://orcid.org/0000-0003-3345-3965
Chin, Suet-Feung http://orcid.org/0000-0001-5697-1082
Rueda, Oscar M. http://orcid.org/0000-0003-0008-4884
Green, Andrew http://orcid.org/0000-0002-0488-5913
Rakha, Emad
Aparicio, Samuel http://orcid.org/0000-0002-0487-9599
Ellis, Ian O. http://orcid.org/0000-0001-5292-8474
Bodenmiller, Bernd http://orcid.org/0000-0002-6325-7861
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Ali, H. Raza http://orcid.org/0000-0001-7587-0906
Article History
Received: 23 September 2021
Accepted: 3 March 2022
First Online: 18 April 2022
Competing interests
: C.C. is a member of AstraZeneca’s iMED External Science Panel and Illumina’s Scientific Advisory Board and a recipient of research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca and Servier. B.B. holds a patent relevant to this work entitled ‘A method for determining the likelihood of a patient being responsive to cancer immunotherapy’ (publication number WO2020207771A1). E.P. has received honoraria from Roche and Novartis for speaking at meetings and Inflection Point Biomedical Advisors for participating in an advisory panel. The other authors declare no competing interests.